Medexus Pharmaceuticals Inc.
MDP.TOTSXHealthcare● Active
$3.95
+$0.04(+1.02%)
Market Cap$127586501
P/E Ratio—
52W High$4.17
52W Low$2.47
Medexus Pharmaceuticals Inc. (MDP.TO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MDP.TO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.00B | ($0.00B) | $0.00B | ($0.00B) | ($0.03B) |
| Depreciation & Amort. | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | $0.01B | ($0.01B) | ($0.02B) | $0.01B | $0.00B |
| Net Cash from Operations | $0.02B | $0.02B | ($0.00B) | ($0.00B) | $0.01B |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.01B) | ($0.01B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.01B) | ($0.00B) | ($0.00B) | ($0.01B) | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.01B) | ($0.03B) | $0.01B | $0.00B | ($0.00B) |
| Net Cash from Financing | $0.00B | ($0.02B) | $0.01B | $0.00B | $0.02B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.02B | $0.02B | ($0.00B) | ($0.01B) | ($0.01B) |
| FCF Margin %(computed) | 19.67% | 16.32% | -1.67% | -11.60% | -7.18% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Medexus Pharmaceuticals Inc. data
About Medexus Pharmaceuticals Inc. (MDP.TO) Cash Flow Statement
Medexus Pharmaceuticals Inc. generated operating cash flow of $0.02B and free cash flow of $0.02B for 2025 — a FCF margin of 19.67%. Capital expenditure was ($0.00B).
Frequently asked questions
MDP.TO · 4 questionsMedexus Pharmaceuticals Inc. generated free cash flow of $0.02B for 2025, up 15.5% year-over-year.
MDP.TO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10